Compare
BPC-157 vs TB-500
These two peptides are the most-discussed pair in the tissue-repair conversation, and they are also the most-conflated. In practice they share none of what usually justifies grouping compounds: their origins are unrelated, their mechanisms are unrelated, and the shape of the evidence supporting each is structurally different. This page walks through those distinctions.
Last reviewed 2026-07-12
Molecular origin
BPC-157
15-amino-acid partial sequence (GEPPPGKPADDAGLV) of a protein originally isolated from human gastric juice at the University of Zagreb. Synthetic peptide.
TB-500
17-amino-acid synthetic fragment (LKKTETQEKNPLPSKETI) of thymosin β4, a 43-amino-acid endogenous protein first isolated from calf thymus. TB-500 is NOT the same molecule as thymosin β4 itself.
2 citations in this row
Proposed mechanism
BPC-157
Multi-pathway modulation proposed in the Sikiric-lab literature: VEGF-mediated angiogenesis, fibroblast migration, nitric-oxide-system modulation. Not a single-receptor drug.
TB-500
Actin cytoskeleton modulation via the N-terminal actin-binding region shared with parent Tβ4. The mechanism is inherited from the parent protein's characterised biology.
2 citations in this row
Evidence-base structure
BPC-157
Large preclinical body of work covering many tissue systems, concentrated in the Sikiric laboratory. Human evidence: small open-label observations in inflammatory bowel disease, primarily from the same laboratory. No completed phase-2 randomised trial anywhere.
TB-500
The impressive Tβ4 human evidence base (RegeneRx phase-1/2 in cardiac, wound, and corneal indications) belongs to the parent protein, not the TB-500 fragment. TB-500-specific human trial data is essentially absent.
4 citations in this row
The 'one laboratory' vs 'wrong molecule' problems
BPC-157
The BPC-157 evidence base is largely from a single laboratory. That does not disqualify it, but it does mean independent external replication of the key claims is a real gap.
TB-500
The TB-500 evidence base has a different problem: much of what is cited for it is actually about the parent Tβ4 protein, not the fragment. Understanding this un-conflation is what allows an informed reading.
WADA / anti-doping status
BPC-157
On the WADA prohibited list under S0 (non-approved substances). A positive test carries doping sanctions independent of clinical justification.
TB-500
On the WADA prohibited list under S2 (peptide hormones, growth factors, related substances). Also prohibited under most major racing-authority anti-doping rules — the compound's veterinary-doping history is part of its identifiable regulatory record.
1 citation in this row
Where each compound is typically discussed
BPC-157
Tendon and ligament injury recovery contexts (Chang 2011 is the anchoring paper), gastric-tract healing, general soft-tissue repair conversations.
TB-500
Systemic soft-tissue and connective-tissue recovery. The equine-veterinary origin persists in the compound's identifiable profile even though that market has receded.
1 citation in this row
When they're used together
BPC-157
The 'BPC-157 + TB-500 stack' is one of the most common research-context combinations in the tissue-repair space. The mechanistic rationale is that different proposed pathways would be additive rather than redundant.
TB-500
Same rationale from the other side. Whether that additivity actually manifests in humans has never been characterised in a controlled trial — the combination is a research-community convention, not an evidence-based protocol.
The best way to think about BPC-157 and TB-500 is not as sibling compounds but as two independently interesting research peptides that happen to occupy adjacent conversational space. BPC-157's evidence base is preclinical-heavy and single-lab-concentrated. TB-500's evidence base is largely inherited from a related-but-different molecule. Neither compound has a controlled human trial supporting the applications for which it is popularly used. Reading each on its own terms is what allows an honest assessment.
References
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract· Sikiric P, Seiwerth S, Rucman R, et al. · 2010
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration· Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS · 2011
- BPC 157 and Standard Angiogenic Growth Factors — Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing· Seiwerth S, Milavic M, Vukojevic J, et al. · 2019
- Thymosin beta 4: actin-sequestering protein moonlights to repair injured tissues· Goldstein AL, Hannappel E, Kleinman HK · 2005
- Thymosin beta4 accelerates wound healing· Malinda KM, Sidhu GS, Mani H, et al. · 1999
- Thymosin beta4: structure, function, and biological properties supporting current and future clinical applications· Crockford D, Turjman N, Allan C, Angel J · 2010
- Preclinical safety assessment of Thymosin β4 for the treatment of patients with damaged heart tissue· Ruff D, Crockford D, Girardi G, Zhang Y · 2010
- World Anti-Doping Agency (WADA) Prohibited List — S2 peptide hormones, growth factors, related substances, and mimetics· World Anti-Doping Agency · 2024
Continue exploring
Editorial paths through the library. Pick one and follow the trail.
Compare
Semaglutide vs Tirzepatide
Two of the most extensively studied incretin-based therapies — approved and marketed in the same therapeutic areas, but with different receptor profiles, different phase-3 programs, and different published outcomes. This page compares what the peer-reviewed literature and regulatory documentation currently support for each.
→
Compare
Tirzepatide vs Retatrutide
Two incretin-based peptides in the same broad family, but at very different stages of development. This page compares what the peer-reviewed literature currently supports on each — regulatory status, receptor targets, evidence tier, and headline efficacy from published phase-3 trials.
→
Compare
KPV vs GHK-Cu
Two small, endogenously-derived peptides that get grouped in discussions about anti-inflammatory and skin peptides. They share molecular scale — both are tripeptides — and their mechanisms are both proposed to be intracellular rather than classical receptor-mediated. Everything else about their evidence structures, use cases, and regulatory status differs, in ways that are worth reading precisely.
→
Compare
Tesamorelin vs Sermorelin
Two GHRH analogues built for the same fundamental job — stimulating the pituitary's own pulsatile release of growth hormone — but at very different points in structure, half-life, and regulatory history. This page compares what the peer-reviewed literature and regulatory documentation currently support for each.
→
Compare
CJC-1295 (No DAC) vs Sermorelin
Two GHRH(1-29)-based signals. Sermorelin is the native sequence; CJC-1295 No DAC is the same sequence with four amino acid substitutions that resist enzymatic degradation. This page compares what the peer-reviewed literature currently supports on each.
→
Compare
CJC-1295 No DAC vs CJC-1295 DAC
The two forms share an identical GHRH(1-29) backbone with the same four amino acid substitutions. The Drug Affinity Complex (DAC) — a single maleimidopropionic acid linker that covalently binds serum albumin — is the only chemical difference. Every downstream pharmacologic property flows from that one addition. This page reads out those differences precisely.
→
Compare
AOD-9604 vs Semaglutide
Two compounds pursued as pharmacological approaches to weight loss, from opposite starting points and with opposite clinical results. AOD-9604 was designed as a lipolytic fragment of human growth hormone; its 2007 phase 2b did not meet its primary endpoint and its pharmaceutical program was discontinued. Semaglutide came from the incretin research tradition, obtained FDA approval for chronic weight management in 2021, and produced a large clinical evidence base. This page presents the two side by side to make each visible in the other's context.
→
Categories
Fat Loss & Metabolism
Compounds studied for body-composition, glycaemic control, and metabolic health.
→
Categories
Repair & Regeneration
Compounds studied for wound healing, tissue repair, and musculoskeletal recovery.
→